PD-1 inhibitor， bevacizumab
Phase 2Monoclonal antibody
PD-1 inhibitor， bevacizumab is one of 7 small molecule programs targeting PD-1antibody. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Pd-1antibody
#DrugCompanyPhaseTrials
1Kuvan
BioMarin PharmaceuticalPhase 2
Libtayo
RegeneronPhase 2
Opzelura
DDizal Pharmaceuticals
Phase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Chidamide
CChipscreen Biosciences, Ltd.
Phase 2
L-DEP and PD-1 Antibody
BBeijing Friendship Hospital
Phase 3
PD-1 inhibitor， bevacizumab
WWomen's Hospital School Of Medicine Zhejiang University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-1 inhibitor， bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details